2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3138 N-acetylcysteine preserves hematopoietic stem cell function after inflammatory oxidative stress without reducing cumulative cell division

Xin Huang, BS, BA, Camille Brzechffa, BA2, Kiana Kalei Kaumaka Guillermo, MSc3, Lucas Wadley, PhD, BS4, Angela Fleischman, MD, PhD5
1 University of California, Irvine, Irvine, California, United States
2 University of California, Irvine, Irvine, California, United States
3 University of California, Irvine, Irvine, California, United States
4 University of California, Irvine, Irvine, California, United States
5 University of California, Irvine, Irvine, California, United States

Aging is associated with reduced hematopoietic stem cell (HSC) fitness, chronic inflammation, and increased oxidative stress, yet the relationship between inflammatory reactive oxygen species (ROS), HSC proliferation, and functional decline remains incompletely understood. We hypothesized that inflammatory ROS represents a modifiable determinant of HSC dysfunction that can be therapeutically targeted to preserve hematopoietic fitness during aging.

To define the temporal relationship between inflammatory ROS and HSC proliferation, mice received a single intraperitoneal injection of lipopolysaccharide (LPS, 5 μg), and bone marrow was harvested from 2–72 hours for CellROX and BrdU analysis by flow cytometry to quantify ROS and proliferation, respectively. To determine the effects of chronic ROS suppression, H2B-GFP label-retaining mice underwent repeated LPS challenge with or without N-acetylcysteine (NAC) supplementation for four weeks, followed by analysis of cumulative division history by GFP dilution. Functional consequences were evaluated by competitive transplantation of bone marrow from NAC-treated or water-treated donors into lethally irradiated recipients with congenically marked young competitor marrow. Additional studies assessed the impact of NAC on natural aging and on long-term regenerative capacity using serial transplantation.

Acute inflammatory stress induced temporally distinct oxidative and proliferative responses in HSC-enriched populations. CellROX fluorescence peaked around 16 hours after LPS exposure, whereas BrdU incorporation peaked later, around 48 hours, indicating that inflammatory ROS induction precedes with subsequent proliferative activation. As a next step, we will test whether NAC reduces LPS-induced HSC proliferation in the acute inflammatory setting and whether ROS reduction correlates with reduced cell-cycle entry.

We next examined the impact of chronic inflammation (LPS 5 μg/day IP, 5 days/week, for 4 weeks) on HSC proliferative history and functional decline, and asked whether NAC would alter these outcomes. H2B-GFP label retaining mice allowed us to directly quantify divisional history. NAC attenuated ROS accumulation across HSPC populations. Surprisingly, this suppression of ROS did not reduce cumulative HSC proliferative history as measured by H2B-GFP dilution. Despite unchanged division number, bone marrow from NAC plus LPS treated mice performed equivalently to unexposed bone marrow in competitive transplants, whereas LPS only bone marrow was functionally inferior in competitive repopulation assays. This dissociation suggests NAC protects HSC fitness under chronic inflammatory stress without simply blocking division. To test this directly, we are sorting GFP of various intensity, reflecting divisional history, from vehicle and NAC-exposed mice for competitive transplantation to determine whether NAC preserves function specifically in extensively divided HSC.

We next tested whether NAC extends HSC functional lifespan using serial transplantation. NAC was administered after the initial transplant to simulate antioxidant exposure once some HSC damage had already occurred, and bone marrow was then serially transplanted without further NAC exposure. By the tertiary transplant, approximately 30% of water exposed recipients failed to engraft, while all NAC treated groups showed adequate engraftment. Quaternary transplant results are forthcoming.

Together, these findings suggest that inflammatory oxidative stress contributes to age-associated HSC dysfunction independent of cumulative proliferative history and raise the possibility that antioxidant therapy preserves the functional integrity of repeatedly divided HSC rather than simply preventing proliferation.

NAC protects HSC from inflammatory oxidative stress and preserves functional fitness independent of cumulative cell division, positioning inflammatory ROS as an early and therapeutically targetable driver of HSC exhaustion. Ongoing studies sorting HSC across defined division states will determine whether NAC selectively preserves the regenerative capacity of extensively divided HSC. These results identify oxidative stress as a modifiable driver of hematopoietic aging and suggest antioxidant strategies may reduce the selective pressures that promote age-related clonal hematopoiesis.

Xin Huang, BS, BA: No relevant conflicts of interest to declare.